KR102402806B1 - 유전자 변형된 비-인간 동물 및 그것의 사용 방법 - Google Patents

유전자 변형된 비-인간 동물 및 그것의 사용 방법 Download PDF

Info

Publication number
KR102402806B1
KR102402806B1 KR1020217020816A KR20217020816A KR102402806B1 KR 102402806 B1 KR102402806 B1 KR 102402806B1 KR 1020217020816 A KR1020217020816 A KR 1020217020816A KR 20217020816 A KR20217020816 A KR 20217020816A KR 102402806 B1 KR102402806 B1 KR 102402806B1
Authority
KR
South Korea
Prior art keywords
human
cells
rodent
genetically modified
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217020816A
Other languages
English (en)
Korean (ko)
Other versions
KR20210087567A (ko
Inventor
리챠드 플라벨
틸 스트로윅
마르쿠스 지. 만츠
시아라 보르소티
마드하브 도답카르
앤드류 제이. 머피
션 스티븐스
죠지 디. 얀코파울로스
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
예일 유니버시티
인스티튜트 포 리서치 인 바이오메드슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드, 예일 유니버시티, 인스티튜트 포 리서치 인 바이오메드슨 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020227017372A priority Critical patent/KR102458016B1/ko
Publication of KR20210087567A publication Critical patent/KR20210087567A/ko
Application granted granted Critical
Publication of KR102402806B1 publication Critical patent/KR102402806B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020217020816A 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법 Active KR102402806B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227017372A KR102458016B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261722437P 2012-11-05 2012-11-05
US61/722,437 2012-11-05
PCT/US2013/068569 WO2014071397A2 (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof
KR1020157011974A KR102275412B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157011974A Division KR102275412B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017372A Division KR102458016B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법

Publications (2)

Publication Number Publication Date
KR20210087567A KR20210087567A (ko) 2021-07-12
KR102402806B1 true KR102402806B1 (ko) 2022-05-30

Family

ID=49876957

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020227017372A Active KR102458016B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR1020157011974A Active KR102275412B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR1020227036338A Active KR102649893B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR1020247008928A Active KR102768101B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR1020217020816A Active KR102402806B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법

Family Applications Before (4)

Application Number Title Priority Date Filing Date
KR1020227017372A Active KR102458016B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR1020157011974A Active KR102275412B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR1020227036338A Active KR102649893B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법
KR1020247008928A Active KR102768101B1 (ko) 2012-11-05 2013-11-05 유전자 변형된 비-인간 동물 및 그것의 사용 방법

Country Status (19)

Country Link
US (5) US9901082B2 (enExample)
EP (5) EP2914102B1 (enExample)
JP (5) JP6422441B2 (enExample)
KR (5) KR102458016B1 (enExample)
CN (3) CN108401987B (enExample)
AU (3) AU2013337242B2 (enExample)
CA (1) CA2887706C (enExample)
DK (4) DK3939423T3 (enExample)
ES (4) ES2748662T3 (enExample)
FI (1) FI3939423T3 (enExample)
IL (5) IL311744B2 (enExample)
MX (3) MX370856B (enExample)
MY (1) MY175400A (enExample)
NO (1) NO2946162T3 (enExample)
NZ (3) NZ749626A (enExample)
PT (4) PT3939423T (enExample)
RU (1) RU2673156C2 (enExample)
SG (2) SG11201502685XA (enExample)
WO (1) WO2014071397A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
DK3417701T3 (da) 2009-10-06 2022-03-14 Regeneron Pharma Genmodificerede mus og indpodning
MX338971B (es) 2011-02-15 2016-05-06 Inst Res Biomedicine Irb Ratones de m-csf humanizada.
CN120718856A (zh) 2012-09-07 2025-09-30 再生元制药公司 经遗传修饰的非人动物及其使用方法
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
SMT201900429T1 (it) 2013-02-20 2019-09-09 Regeneron Pharma Topi esprimenti co-recettori umanizzati linfociti t
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
DK4269430T3 (da) 2013-09-23 2025-08-18 Regeneron Pharma Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen
SI3138397T1 (sl) 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
KR102173297B1 (ko) 2013-11-19 2020-11-03 리제너론 파마슈티칼스 인코포레이티드 인간화된 증식-유도 리간드 유전자를 가지고 있는 비-인간 동물
MY183188A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
ES2794942T3 (es) 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
EP3136850A1 (en) 2014-04-28 2017-03-08 Recombinetics, Inc. Multiplex gene editing in swine
JP6598798B2 (ja) 2014-05-05 2019-10-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｃ５およびｃ３動物
NO2785538T3 (enExample) 2014-05-07 2018-08-04
EP4306648A3 (en) 2014-05-19 2024-04-17 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing human epo
WO2015196051A1 (en) 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
RS63410B1 (sr) 2014-11-24 2022-08-31 Regeneron Pharma Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
BR112017010490A2 (pt) 2014-12-05 2018-04-03 Regeneron Pharma roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
LT3230320T (lt) 2014-12-09 2021-01-11 Regeneron Pharmaceuticals, Inc. Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 274 geną
WO2016137841A1 (en) * 2015-02-26 2016-09-01 William Paterson University Of New Jersey Transgenic mice
DK3280257T3 (da) 2015-04-06 2023-09-04 Regeneron Pharma Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr
PT3282835T (pt) * 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
LT3376857T (lt) 2015-11-20 2021-06-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
AU2017308121A1 (en) * 2016-08-11 2019-03-07 The Jackson Laboratory Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
WO2018102546A1 (en) * 2016-11-30 2018-06-07 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
AU2018224227A1 (en) * 2017-02-27 2019-08-29 Regeneron Pharmaceuticals, Inc. Non-human animal models of Retinoschisis
CN107115424B (zh) * 2017-05-09 2018-05-29 江西樟树市正康医药生物科技有限公司 改变酸性体质保钙及清热解毒的中药组合物及制备方法
WO2018209344A1 (en) 2017-05-12 2018-11-15 The Jackson Laboratory Nsg mice lacking mhc class i and class ii
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
US11712026B2 (en) 2017-10-18 2023-08-01 The Jackson Laboratory Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
AU2018375796B2 (en) 2017-11-30 2024-11-21 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TRKB locus
JP7393342B2 (ja) 2018-03-21 2023-12-06 エーエルエックス オンコロジー インコーポレイテッド シグナル調節タンパク質αに対する抗体及び使用方法
AU2019242586B2 (en) 2018-03-26 2025-09-11 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
PL3823443T3 (pl) 2018-07-16 2024-09-23 Regeneron Pharmaceuticals, Inc. Modele gryzoni z chorobą ditra i ich zastosowania
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111057721B (zh) * 2018-10-12 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化IL-4和/或IL-4Rα改造动物模型的制备方法及应用
CN111172190B (zh) * 2018-12-25 2021-07-30 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf2基因改造非人动物的构建方法及应用
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
SG11202111256XA (en) 2019-06-07 2021-11-29 Regeneron Pharma Non-human animals comprising a humanized albumin locus
US20220354098A1 (en) * 2019-07-17 2022-11-10 Yale University Genetically Modified Non-Human Animals and Methods of Use Thereof
CN111304246B (zh) * 2019-12-17 2021-05-04 百奥赛图江苏基因生物技术有限公司 一种人源化细胞因子动物模型、制备方法及应用
EP4087392A4 (en) * 2020-01-10 2024-02-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC MHC PROTEIN COMPLEX
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
KR20230074758A (ko) 2020-09-24 2023-05-31 더 잭슨 래보라토리 면역 세포 요법을 평가하기 위한 인간화 마우스 모델
AU2022249328A1 (en) 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
CN116918767A (zh) * 2022-04-07 2023-10-24 上海立迪生物技术股份有限公司 一种人all小鼠原位pdox模型的建立方法及应用
CN116918766A (zh) * 2022-04-07 2023-10-24 上海立迪生物技术股份有限公司 一种人aml小鼠原位pdox模型的建立方法及应用
CA3260622A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. GENETICALLY MODIFIED ANIMAL MODEL AND ITS USE TO MODEL THE HUMAN IMMUNE SYSTEM
US20240415103A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2025250495A1 (en) * 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1988003173A2 (en) 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
DE3853201T2 (de) 1987-12-23 1995-09-14 Univ Leland Stanford Junior Schimäre immunkompromittierende Säugetiere und ihre Verwendung.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
JP2935511B2 (ja) * 1989-10-20 1999-08-16 忠三 岸本 ヒトｉｌ―６レセプターの製造方法
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DE69131331T2 (de) 1990-01-15 2000-03-02 Yeda Research And Development Co., Ltd. Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren
DE69120890T2 (de) 1990-05-03 1997-02-20 Systemix Inc Menschliches lymph-gewebe in einem wirt mit angegriffenem immunsystem
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
EP0484512A4 (en) 1990-05-25 1993-05-05 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
CA2103705C (en) 1991-02-11 1996-01-30 Ayub K. Ommaya Spinal fluid driven artificial organ
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
DE69229254T2 (de) 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
US5663481A (en) 1993-08-06 1997-09-02 Mount Sinai Hospital Corporation Animal model of the human immune system
JPH10503092A (ja) 1994-07-27 1998-03-24 メルク エンド カンパニー インコーポレーテッド ブラジキニンｂ２受容体が改変されたトランスジェニック非ヒト動物
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
JP4312265B2 (ja) 1997-04-09 2009-08-12 ラング−ジ チャン ワクチン評価のための動物モデル
GB2337755B (en) * 1998-05-29 2003-10-29 Secr Defence Virus vaccine
CA2382383A1 (en) * 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
JP2004500810A (ja) 1999-12-09 2004-01-15 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド Ｉｌ−６様ポリヌクレオチド、ポリペプチド、および抗体
WO2002022786A1 (en) 2000-09-14 2002-03-21 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR101015913B1 (ko) * 2001-07-10 2011-02-23 존슨 앤드 존슨 리서치 피티와이 리미티드 조혈모세포의 유전적 변이 치료 방법 및 변이 세포의 용도
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
US20050177884A1 (en) 2001-11-15 2005-08-11 Kirin Beer Kabushiki Kaisha Chimeric nonhuman animal
AU2003281309A1 (en) 2002-07-05 2004-01-23 Kirin Beer Kabushiki Kaisha Novel undifferentiated stem cells contained in cord blood, bone marrow, peripheral blood or the like
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
EP1539946A4 (en) 2002-09-09 2006-03-15 California Inst Of Techn METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
AU2003297023A1 (en) 2002-12-16 2004-07-29 Genentech, Inc. Transgenic mice expressing human cd20
CN104001158A (zh) * 2003-03-12 2014-08-27 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
PL1802193T3 (pl) 2004-10-19 2014-09-30 Regeneron Pharma Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
AU2007244826B2 (en) 2006-04-25 2013-04-11 The Regents Of The University Of California Administration of growth factors for the treatment of CNS disorders
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
US20080081064A1 (en) 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
EP2088854A1 (en) 2006-12-05 2009-08-19 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
WO2008153742A2 (en) 2007-05-23 2008-12-18 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
US20110118446A1 (en) 2007-09-28 2011-05-19 The General Hospital Corporation Methods and compositions for antibody production
WO2009097468A2 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
SG175127A1 (en) * 2009-04-13 2011-11-28 Apceth Gmbh & Co Kg Engineered mesenchymal stem cells and method of using same to treat tumors
WO2011002721A1 (en) 2009-06-29 2011-01-06 Leskov Ilya B Non-human mammal model of human hematopoietic cancer
JP2012531896A (ja) 2009-06-29 2012-12-13 チェン，チンフェン ヒト化非ヒト哺乳動物を製造する方法
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
DK3417701T3 (da) * 2009-10-06 2022-03-14 Regeneron Pharma Genmodificerede mus og indpodning
EP3336102A3 (en) * 2009-12-21 2018-08-01 Regeneron Pharmaceuticals, Inc. Humanized fc gamma r mice
EP2618656B1 (en) 2010-09-20 2018-06-20 Yale University, Inc. HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
MX338971B (es) 2011-02-15 2016-05-06 Inst Res Biomedicine Irb Ratones de m-csf humanizada.
WO2013063556A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
CN120718856A (zh) 2012-09-07 2025-09-30 再生元制药公司 经遗传修饰的非人动物及其使用方法
ES2748662T3 (es) 2012-11-05 2020-03-17 Institute For Res In Biomedicine Irb Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
DK4269430T3 (da) 2013-09-23 2025-08-18 Regeneron Pharma Ikke-menneskelige dyr, der har et humaniseret signalregulerende proteingen
SI3138397T1 (sl) 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
EP4306648A3 (en) 2014-05-19 2024-04-17 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing human epo
PT3282835T (pt) 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
American j. Pathology vol.157 no.5 pp.1485-1493(2000.11.30)
J. Exper. Med. vol.185 no.4 pp.755-766(1997.02.17)
Proc. Natl. Acad. Sci. USA vol.86 no.19 pp.7547-7551(1989.10.31)
Proc. Natl. Acad. Sci. USA vol.92 pp.4862-4866(1995.05.31)

Also Published As

Publication number Publication date
PT3308641T (pt) 2019-10-24
HK1210380A1 (en) 2016-04-22
DK3556206T3 (da) 2021-08-09
JP2022132376A (ja) 2022-09-08
DK3939423T3 (da) 2024-05-06
HK1253909A1 (en) 2019-07-05
JP7105844B2 (ja) 2022-07-25
EP3308641A1 (en) 2018-04-18
NZ724353A (en) 2022-05-27
EP3556206A1 (en) 2019-10-23
RU2673156C2 (ru) 2018-11-22
MX370856B (es) 2020-01-08
KR20220148307A (ko) 2022-11-04
EP4389764A2 (en) 2024-06-26
SG11201502685XA (en) 2015-05-28
JP2021010371A (ja) 2021-02-04
NZ631614A (en) 2016-10-28
EP2914102B1 (en) 2017-10-18
CA2887706C (en) 2022-08-02
IL270124A (enExample) 2019-12-31
KR102649893B1 (ko) 2024-03-25
KR102768101B1 (ko) 2025-02-18
JP7579304B2 (ja) 2024-11-07
EP3939423A1 (en) 2022-01-19
SG10201707449TA (en) 2017-10-30
ES2983031T3 (es) 2024-10-21
IL299887A (en) 2023-03-01
CA2887706A1 (en) 2014-05-08
CN114766432A (zh) 2022-07-22
RU2018140189A (ru) 2018-12-10
EP3308641B1 (en) 2019-07-03
IL258968A (en) 2018-06-28
IL238478A0 (en) 2015-06-30
RU2015121195A (ru) 2016-12-27
NO2946162T3 (enExample) 2018-06-09
IL299887B2 (en) 2024-09-01
IL311744A (en) 2024-05-01
MX377561B (es) 2025-03-10
KR102275412B1 (ko) 2021-07-12
WO2014071397A2 (en) 2014-05-08
US20210100228A1 (en) 2021-04-08
KR20240042142A (ko) 2024-04-01
JP6772234B2 (ja) 2020-10-21
US10785968B2 (en) 2020-09-29
MY175400A (en) 2020-06-24
US9901082B2 (en) 2018-02-27
CN104918483B (zh) 2018-05-11
IL270124B2 (en) 2023-06-01
IL311744B1 (en) 2025-06-01
MX2020012427A (es) 2022-06-08
IL299887B1 (en) 2024-05-01
CN108401987A (zh) 2018-08-17
KR20150081285A (ko) 2015-07-13
US20240099278A1 (en) 2024-03-28
WO2014071397A3 (en) 2014-06-26
NZ749626A (en) 2023-11-24
KR102458016B1 (ko) 2022-10-25
US20180049413A1 (en) 2018-02-22
PT3939423T (pt) 2024-05-29
US11778995B2 (en) 2023-10-10
FI3939423T3 (fi) 2024-05-23
CN108401987B (zh) 2022-04-29
JP2025010204A (ja) 2025-01-20
DK3308641T3 (da) 2019-10-07
RU2018140189A3 (enExample) 2022-05-04
EP4389764A3 (en) 2024-08-14
CN104918483A (zh) 2015-09-16
AU2022200302B2 (en) 2025-04-10
MX2015005654A (es) 2016-04-28
AU2013337242B2 (en) 2019-04-04
EP3556206B1 (en) 2021-06-02
JP2019037238A (ja) 2019-03-14
AU2019204775A1 (en) 2019-07-25
JP6422441B2 (ja) 2018-11-14
MX2019015882A (es) 2020-02-07
ES2884598T3 (es) 2021-12-10
DK2914102T3 (en) 2017-12-11
AU2022200302A1 (en) 2022-02-10
IL311744B2 (en) 2025-10-01
IL270124B1 (enExample) 2023-02-01
KR20210087567A (ko) 2021-07-12
PT2914102T (pt) 2018-01-15
IL258968B (en) 2019-10-31
CN114766432B (zh) 2024-08-02
US9986724B2 (en) 2018-06-05
US20140134662A1 (en) 2014-05-15
ES2748662T3 (es) 2020-03-17
KR20220075242A (ko) 2022-06-07
ES2655442T3 (es) 2018-02-20
EP2914102A2 (en) 2015-09-09
AU2013337242A1 (en) 2015-04-30
EP3939423B1 (en) 2024-03-06
US20160366862A1 (en) 2016-12-22
AU2019204775B2 (en) 2021-10-21
PT3556206T (pt) 2021-08-24
IL238478B (en) 2018-05-31
JP2015534819A (ja) 2015-12-07

Similar Documents

Publication Publication Date Title
JP7579304B2 (ja) 遺伝学的に修飾された非ヒト動物およびその使用法
HK40111833A (en) Genetically modified non-human animals and methods of use thereof
HK40068456B (en) Genetically modified non-human animals and methods of use thereof
HK40068456A (en) Genetically modified non-human animals and methods of use thereof
HK40016315B (en) Genetically modified non-human animals and methods of use thereof
HK40016315A (en) Genetically modified non-human animals and methods of use thereof
HK1253909B (en) Immunodeficient, genetically modified rodent and methods of use thereof
HK1210380B (en) Genetically modified non-human animals and methods of use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210702

Application number text: 1020157011974

Filing date: 20150507

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210729

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210809

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220224

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220524

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220525

End annual number: 3

Start annual number: 1

PG1601 Publication of registration